Cardiff Biologicals

RNS Number:9262E
Biofusion PLC
02 October 2007


For immediate release                                            2 October 2007


                                 BIOFUSION PLC
                         ("Biofusion" or "the Company")

 
                  TRANSFER OF CARDIFF BIOLOGICALS TO BIOFUSION
                                     AND
                       INVESTMENT IN CARDIFF BIOLOGICALS 


Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, is today pleased to announce that under its
agreement with Cardiff University, the University's 25% stake in Cardiff
Biologicals Limited ("Cardiff Biologicals"), a drug discovery and development
company specialising in anti-angiogenesis products for the treatment of cancer,
has been transferred to Biofusion, for a loan note to the value of #250,000.

In addition, Biofusion announces that it has invested #200,000 into Cardiff
Biologicals, thereby bringing its total shareholding in the company to 50%. The
funding will be utilised by Cardiff Biologicals to continue development of its
lead anti-angiogenesis compound for the treatment of cancer, which is currently
poised to enter the pre-clinical phase of its development.

Cardiff Biological's technology is based on research conducted by Professor Wen
Jiang' at Cardiff University.

For further information about Biofusion or Cardiff Biologicals please contact:


Biofusion                                                   [phone]
                                                                          
David Baynes, CEO


Cardiff Biologicals                                                          
                                                            [phone]
Jon Dickens


Buchanan Communications                                     [phone]
                                                                          
Lisa Baderoon / Mary-Jane Johnson / Catherine Breen


Nomura Code                                                 [phone]
                                                                          
Phil Walker / Clare Terlouw


About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately #114 million a
year. The Company has a portfolio of over 20 spin-out companies.

Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of Sheffield University spin-out companies including Asterion, Axordia,
Celltran, Lifestyle Choices, Diurnal and Phase Focus. The University of
Sheffield was ranked 5th in the UK for the quality of its life sciences research
and will be spending an estimated #0.5bn of research funding over the lifetime
over the life of the Sheffield Agreement.

In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP. Biofusion has shareholdings in a portfolio of Cardiff
University spin-out companies including Abcellute and Q-Chip. Cardiff University
was ranked 7th in the UK in the most recent research rankings and will be
spending over #1.0bn of research funding over the lifetime over the life of the
Cardiff Agreement.

www.biofusion.co.uk


About Cardiff Biologicals

Cardiff Biological's technology is based on Professor Wen Jiang's research
specialising in anti-angiogenesis products for the treatment of cancer. Cardiff
Biological's lead compound is KVE702, a novel, hybrid molecule combining
anti-angiogenic activity and endothelial cell regulatory activity. KVE702 has
completed its research phase and is now ready to enter full development. This
protein comprises two functional sequences each with a different mode of action
and so has the potential for dual action giving rise to a greater
anti-angiogenic activity.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCOKDKDFBDDBKK